Kazakhstan greenlights $80mn pharmaceutical plant in latest push for domestic drug self-sufficiency

Kazakhstan has approved an investment agreement underpinning a 42.5bn tenge (around $80mn) pharmaceutical production complex in the central region of Karaganda, in the latest step of a state-driven campaign to reduce the country's reliance on imported medicines and build a domestic manufacturing base in higher-value therapeutic categories.

The Kazakh government, under prime minister Olzhas Bektenov, signed the agreement between the health ministry and the Karaganda Pharmaceutical Complex on Thursday. The project, financed wholly through private investment, will involve the construction and modernisation of pharmaceutical production facilities, and is being framed by Astana as one of the largest investment projects in the country's pharmaceutical sector.

The complex is intended to produce 74 types of pharmaceuticals, including medicines for cancer, autoimmune and rare diseases — categories that have until now been almost entirely served by imports in the Kazakh market. Beyond finished-dose manufacturing, the facility will house production capacity for immunobiological products and for the synthesis of active pharmaceutical ingredients, biological products and biotechnological products to international standards. The plant is expected to create approximately 70 high-skilled permanent jobs.

The investment forms part of a broader industrial strategy directed by Kazakh president Kassym-Jomart Tokayev, who has identified domestic pharmaceutical manufacturing as a strategic priority. Government officials describe the policy as one of import substitution and pharmaceutical security — twin goals that have moved up the political agenda in Central Asia and across the post-Soviet space in the wake of the Covid-19 pandemic, the disruption of global supply chains under successive geopolitical shocks, and the heightened focus on national resilience in critical industries.

The numbers underlying the strategy show clear momentum. Kazakhstan's pharmaceutical production rose 8.7 per cent year-on-year in 2025 to 191.1bn tenge, while annual investment in the sector increased from $91.3mn to $142.8mn. Since December 2025, the government has signed seven investment agreements in the industry worth a combined 360bn tenge, with the projects collectively expected to produce around 474 types of pharmaceuticals and create more than 1,170 permanent jobs.

The strategic context is more significant than the headline numbers suggest. Like many former Soviet states, Kazakhstan inherited a fragmented and dilapidated pharmaceutical manufacturing capacity that left it heavily dependent on imports from Russia, India, China and Western Europe for the bulk of its medicines. Successive governments have struggled to attract sustained foreign direct investment into the sector, hampered by limited domestic market scale, the dominance of state procurement and a regulatory environment perceived by international companies as inconsistent. The current wave of state-backed investment agreements is intended to address those constraints by directing capital toward modern, internationally compliant manufacturing infrastructure.

The choice of Karaganda — historically one of the country's industrial and mining centres — is also instructive. The region has been positioning itself as a destination for diversified manufacturing investment as Kazakhstan attempts to broaden the industrial base beyond its dominant hydrocarbon and minerals sectors. A high-tech pharmaceutical complex of this scale, particularly one focused on oncology, autoimmune, rare-disease and biological products, sends a signal about the kind of value-added manufacturing the government is seeking to attract.

There are, however, structural questions about how rapidly Kazakhstan can ascend the value chain in pharmaceuticals. Production of innovative medicines for oncology and rare diseases typically requires not only manufacturing capacity but also access to active pharmaceutical ingredients, validated processes, regulatory expertise and technology transfer arrangements — all of which are difficult to develop in isolation. The plant's stated ambition to synthesise APIs and biotechnological products domestically would represent a meaningful step up the technology curve, if it can be executed at international quality standards.

For the global pharmaceutical industry, the development carries modest but symbolic significance. Central Asia has historically been a peripheral market for Western drugmakers, characterised by limited population scale, fragmented purchasing and uneven regulatory environments. The emergence of a more credible domestic manufacturing base — particularly one capable of producing biologics and high-complexity therapeutics — could shift the dynamics of how multinational pharmaceutical groups engage with the region, whether through technology licensing, joint ventures, contract manufacturing arrangements or direct competition with state-favoured local champions.

For Kazakhstan, the more immediate prize is pharmaceutical security. By onshoring a meaningful slice of domestic demand, particularly in the categories — oncology, autoimmune disease, rare conditions — that command the highest unit costs and the greatest supply chain exposure, the government is betting that a domestic manufacturing base will both reduce the import bill and provide a buffer against the kinds of external shocks that have repeatedly exposed vulnerabilities in global medicines supply over the past five years. Whether the bet pays off will depend less on the headline figures attached to today's investment agreement, and more on the execution discipline brought to its delivery.